Journal
EUROPEAN JOURNAL OF MEDICAL RESEARCH
Volume 26, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40001-021-00606-7
Keywords
Spiramycin; Toxoplasmosis; Systemic protozoa; Sequelae; Mortality; Transmission
Categories
Funding
- National Institute of Allergy and Infectious Diseases [R01AI027530]
- Thrasher Foundation
- Sanofi
Ask authors/readers for more resources
The meta-analysis of 33 studies showed a significant reduction in mother-to-child transmission rates of Toxoplasma gondii following spiramycin treatment in pregnant women.
Purpose We aimed to investigate the effect of antepartum treatment with spiramycin with or without subsequent pyrimethamine-sulfonamide-folinic acid, compared to no treatment, on the rate of mother-to-child transmission (MTCT) of Toxoplasma gondii (T. gondii) and incidence/severity of sequelae in the offspring. Methods Embase and PubMed were searched for literature on spiramycin in pregnant women suspected/diagnosed with T. gondii infection. Meta-analyses were performed using random-effects model. Results Thirty-three studies (32 cohorts and 1 cross-sectional study), with a total of 15,406 mothers and 15,250 offspring, were pooled for analyses. The MTCT rate for all treated patients was significantly lower than the untreated [19.5% (95% CI 14-25.5%) versus 50.7% (95% CI 31.2-70%), p < 0.001]. The transmission rate in patients on spiramycin monotherapy was also significantly lower than untreated [17.6% (95% CI 9.9-26.8%) versus 50.7% (95% CI 31.2-70%), p < 0.001]. Conclusion Results indicate significant reduction in MTCT rates following spiramycin treatment of suspected/diagnosed maternal T. gondii infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available